Galapagos NV

Galapagos announces changes to Executive Committee

22 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

13 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

11 Nov 2022 07:15:00 By Nasdaq GlobeNewswire

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

08 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

04 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

03 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos to host its R&D Update 2022 in New York on 4 November 2022

17 Oct 2022 01:30:00 By Nasdaq GlobeNewswire

Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress

06 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

03 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

27 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

29 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos to present at upcoming investor conferences

24 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

18 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

First key steps in pipeline rebuild and strong commercial progress in H1 2022

04 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

21 Jun 2022 16:03:08 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

20 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from FMR LLC

01 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress

25 May 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plans

06 May 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos demonstrates regulatory and commercial progress in Q1 2022

05 May 2022 16:01:00 By Nasdaq GlobeNewswire